Skip Navigation

Annals of Oncology 2006 17(10):1475-1477; doi:10.1093/annonc/mdl330
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Aebi, S
Right arrow Articles by Castiglione, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aebi, S
Right arrow Articles by Castiglione, M
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

editorial

The enigma of young age

S Aebi1,* and M Castiglione2

1 Department of Medical Oncology, University Hospital Berne, Inselspital PT2C, 3010 Berne, Switzerland
2 International Breast Cancer Study Group Coordinating Center, Bern, Switzerland

*(E-mail: stefan.aebi@insel.ch)

The first 10% of the full text of this article appears below.

Breast cancer in very young patients has traditionally been considered as particularly aggressive and associated with a poor prognosis. The negative prognostic impact of young age has been substantiated in numerous studies of clinical databases [1–4] including a recent population-based analysis of patients with stage I breast cancer: After adjusting for tumor size, histological grade, estrogen receptor (ER) expression, and year of diagnosis, the age at diagnosis was still a significant predictor with each year younger than 45 years adding a relative 5% to the risk of death from breast cancer [5]. The distinction between young and ‘very young’ premenopausal patients is fuzzy but most investigators who chose to dichotomize their analysis used an age limit of 35–40 years.

It appears obvious that age by itself cannot explain the less favorable outlook . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?